Q32 Bio QTTB
Q32 Bio reported a net loss of $8.92 million for the three months ended Sep 30, 2026.
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001193125-26-446206
- Net loss: $8.92 million for the three months ended Sep 30, 2026
- Diluted EPS: -$0.26 for the three months ended Sep 30, 2026
- Cash and equivalents: $289.59 million at Sep 30, 2026
Written from the 10-Q on EDGAR. Check the filing before you rely on it.
What changed since last quarter
2 new risk factors · 4 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| EPS | −$0.26 | −$0.44 | +41% |
| Cash | $289.59M | $106.27M | +173% |
New risk factors (2)
- Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings.
- We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. CMS has advanced several…
Removed risk factors (4)
- Any preliminary or topline data should be viewed with caution until the final data is available. From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient…
- We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Recent CMS proposals, including…
- On May 19, 2025, we received written notice (the "Notice") from the listing qualifications staff of the Nasdaq Stock Market LLC (the "Staff") notifying us that, based on our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which reported our stockholders' equity (deficit) of approximately ($4.0… +3 more paragraphs
- We are subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial condition as well as other disclosure and corporate governance requirements. We qualify as a "smaller…
The reading, claim by claim
- The accompanying notes are an integral part of these condensed consolidated financial statements.
- For the quarter ended September 30, 2026, Q32 Bio Inc. reported: Net income -$8.9 million.
2 of 4 claims matched the filing text.
Not found in the filing text
- The accompanying notes are an integral part of these condensed consolidated financial statements.
- The accompanying notes are an integral part of these condensed consolidated financial statements.
From the filing
Item 1. Financia l Statements.
Item 1. Financia l Statements.
Q32 BIO INC.
CONDENSED CONSOLIDATED B ALANCE SHEETS
(amounts in thousands, except share and per share data)
(UNAUDITED)
September 30,
2026
December 31,
2025
Assets
Current assets:
Cash and cash equivalents
$
289,587
$
48,297
Prepaid expenses and other current assets
1,539
6,753
Total current assets
291,126
55,050
Property and equipment, net
827
979
Right-of-use asset, operating leases
4,601
5,100
Restricted cash and restricted cash equivalents
647
647
Total assets
$
297,201
$
61,776
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
$
1,109
$
879
Accrued expenses and other current liabilities
4,058
4,232
Venture debt, current portion
—
6,235
Total current liabilities
5,167
11,346
Lease liability, net of current portion
4,364
4,943
Venture debt, net of current portion
—
3,473
Total liabilities
9,531
19,762
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2026 and December 31, 2025
—
—
3
2
Additional paid-in capital
518,137
247,005
Accumulated deficit
( 230,470
)
( 204,993
)
Total stockholders' equity
287,670
42,014
Total liabilities and stockholders' equity
$
297,201
$
61,776
The accompanying notes are an integral part of these condensed consolidated financial statements.1
1
Q32 BIO INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPER ATIONS AND COMPREHENSIVE LOSS
(amounts in thousands, except share and per share data)
(UNAUDITED)
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
Operating expenses:
Research and development
$
5,149
$
3,555
$
12,626
$
15,841
General and administrative
5,511
4,022
14,874
13,136
Total operating expenses
10,660
7,577
27,500
28,977
Loss from operations
( 10,660
)
( 7,577
)
( 27,500
)
( 28,977
)
Loss on extinguishment of debt
—
—
( 147
)
—
Other income, net
1,738
188
2,170
1,068
Total other income
1,738
188
2,023
1,068
Net loss and comprehensive loss2
)
$
( 7,389
)
$
( 25,477
)
$
( 27,909
)
Net loss per share—basic and diluted
$
( 0.26
)
$
( 0.60
)
$
( 1.11
)
$
( 2.29
)
Weighted-average common shares—basic and diluted
34,022,755
12,240,542
22,912,875
12,212,081
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
Q32 BIO INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
(amounts in thousands, except share data)
(UNAUDITED)
Common Stock
Additional
Paid in Accumulated
Total
Stockholders'
Equity
Shares
Amount
Capital
Deficit
(Deficit)
Balance as of December 31, 2024
12,197,615
$
2
$
240,487
$
( 234,814
)
$
5,675
Stock-based compensation expense
—
—
1,342
—
1,342
Net loss
—
—
—
( 11,031
)
( 11,031
)
Balance as of March 31, 2025
12,197,615
$
2
$
241,829
$
( 245,845
)
$
( 4,014
)
Stock-based compensation expense
—
—
1,268
—
1,268
Net loss
—
—
—
( 9,489
)
( 9,489
)
Balance as of June 30, 2025
12,197,615
$
2
$
243,097
$
( 255,334
)
$
( 12,235
)
Issuance of common stock from RSU vesting
106,737
—
—
—
—
Stock-based compensation expense
—
—
1,176
—
1,176
Net loss
—
—
—
( 7,389
)
( 7,389
)
Balance as of September 30, 2025
12,304,352
$
2
$
244,273
$
( 262,723
)
$
( 18,448
)
Common Stock
Additional
Paid in Accumulated
Total
Stockholders'
Shares
Amount
Capital
Deficit
Equity
Balance as of December 31, 2025
12,858,047
$
2
$
247,005
$
( 204,993
)
$
42,014
Issuance of common stock and pre-funded warrants in Registered Direct Offering, net of issuance costs
1,666,679
—
10,360
—
10,360
Issuance of common stock from RSU vesting
104,737
—
—
—
—
Stock-based compensation expense
—
—
1,548
—
1,548
Net loss
—
—
—
( 7,609
)
( 7,609
)
Balance as of March 31, 2026
14,629,463
$
2
$
258,913
$
( 212,602
)
$
46,313
Issuance of common stock and pre-funded warrants in private placement, net of issuance costs
6,725,000
1
53,354
—
53,355
Issuance of common stock pursuant to at-the-market offering, net of discounts and issuance costs
2,326,952
—
13,494
—
13,494
Issuance of common stock from option exercises
55,185
—
4
—
4
Stock-based compensation expense
—
—
1,685
—
1,685
Net loss
—
—
—
( 8,946
)
( 8,946
)
Balance as of June 30, 2026
23,736,600
$
3
$
327,450
$
( 221,548
)
$
105,905
Issuance of common stock and pre-funded warrants in Follow-On Financing, net of issuance costs
6,027,399
—
187,501
—
187,501
Issuance of common stock from option exercises
30,666
—
286
—
286
Issuance of common stock from RSU vesting
97,462
—
—
—
—
Stock-based compensation expense
—
—
2,900
—
2,900
Net loss
—
—
—
( 8,922
)
( 8,922
)
Balance as of September 30, 2026
29,892,127
$
3
$
518,137
$
( 230,470
)
$
287,670
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
Q32 BIO INC.
CONDENSED CONSOLIDATED STATEM ENTS OF CASH FLOWS
(amounts in thousands)
(UNAUDITED)
Nine Months Ended
September 30,
2026
2025
Cash flows from operating activities:
Net loss
$
( 25,477
)
$
( 27,909
)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and issuance costs, net of accrued interest
( 34
)
143
Depreciation expense
259
301
Stock-based compensation expense
6,133
3,786
Non-cash lease expense
499
464
Loss on extinguishment of venture debt
147
—
Loss on impairment of equity investment
—
74
Change in fair value of CVR liability
—
( 374
)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
5,214
2,141
Other noncurrent assets
—
116
Accounts payable
210
( 2,016
)
Operating lease liability
( 514
)
( 455
)
Accrued expenses and other current liabilities
( 273
)
( 3,634
)
Net cash used in operating activities
( 13,836
)
( 27,363
)
Cash flows from investing activities:
Purchases of property and equipment
( 52
)
—
Net cash used in investing activities
( 52
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Kiora Pharmaceuticals KPRX public float $10M, Jun 30, 2025
- Brainstorm Cell Therapeutics BCLI public float $10M, Jun 30, 2025
- Scienture Holdings SCNX public float $10M, Jun 30, 2025
- LeonaBio ATHA public float $10M, Jun 30, 2025
- Mannatech MTEX public float $10M, Jun 30, 2025